1MRKX Stock Chart & Stats
€128.70
-€0.22(-0.19%)
At close: 4:00 PM EDT
€128.70
-€0.22(-0.19%)
Day’s Range― - ―
52-Week Range€53.01 - €165.00
Previous CloseN/A
Volume82.00
Average Volume (3M)121.00
Market Cap
€329.20B
Enterprise Value€364.17B
Total Cash (Recent Filing)€7.14B
Total Debt (Recent Filing)€53.91B
Price to Earnings (P/E)152.6
Beta0.21
Next Earnings
Feb 02, 2027EPS Estimate
1.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.26
Shares Outstanding2,467,171,600
10 Day Avg. Volume104
30 Day Avg. Volume121
Financial Highlights & Ratios
PEG Ratio1.81
Price to Book (P/B)5.01
Price to Sales (P/S)4.06
P/FCF Ratio21.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€144.34Price Target Upside12.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
EPS Forecast (FY)2.45
Revenue Forecast (FY)€59.92B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationRobust free cash flow gives Merck internal funding for dividends, share repurchases, debt service, and business development. Healthy conversion from earnings provides resilience while the company invests in launches and its pipeline, although annual cash flow has shown some volatility.
Diversified Growth PortfolioGrowth across oncology, vaccines, animal health, and newer products reduces dependence on any single therapeutic asset. Strong expansion from WELIREG and WINREVAIR, alongside animal-health growth, creates multiple commercial contributors that can support revenue durability.
Pipeline StrengthPositive Phase 3 results for sac-TMT provide evidence that Merck’s late-stage pipeline can add future oncology revenue beyond KEYTRUDA. Meaningful survival benefits and potential regulatory progress strengthen the company’s ability to replenish growth as older products mature.
Bears Say
Upcoming Loss-of-Exclusivity HeadwindsGeneric competition and loss of exclusivity affecting BRIDION, Januvia, and Adempas create a visible medium-term revenue drag. Management expects more than $2 billion of pressure in 2027, requiring new launches and pipeline assets to offset erosion from established products.
Lower Profitability And Higher LeverageThe sharp TTM decline in net income and net margin reduces earnings predictability and weakens returns on the existing capital base. Higher leverage further limits flexibility if profitability remains pressured, even though Merck still generates substantial cash and retains sizeable assets.
Rising Investment CostsHigher operating expenses reflect investment in launches and the pipeline, but they can suppress near-term margins before those programs generate meaningful revenue. Continued mid-to-high single-digit expense growth increases execution demands and makes earnings more sensitive to commercial timing.
Merck & Company News
1MRKX FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was €53.01 and its highest was €165.00 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is €329.20B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Feb 02, 2027 which is in 94 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Oct 29, 2026. The company reported €2.222 earnings per share for the quarter, beating the consensus estimate of €1.861 by €0.361.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company does not currently pay dividends.
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 1.6.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,467,171,600 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of €2.222 in its last earnings report, beating expectations of €1.861. Following the earnings report the stock price went up 4.877%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in IT:1MRKX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€144.34 (12.16% Upside)
€144.34 (12.16% Upside)
Blogger Sentiment
Bullish
IT:1MRKX Sentiment 76%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth €26.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.38%
12-Months-Change
Fundamentals
Return on Equity
5.10%
Trailing 12-Months
Asset Growth
―
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Merck & Company
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
1MRKX Company Deck
1MRKX Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive, with solid third-quarter revenue growth, raised 2026 guidance, strong performance from KEYTRUDA, WELIREG, WINREVAIR, Gardasil, and animal health, and multiple favorable clinical and regulatory milestones. Management expressed increased confidence in the pipeline and long-term growth beyond the KEYTRUDA loss-of-exclusivity period. Offsetting concerns included 2027 generic and loss-of-exclusivity headwinds, moderating KEYTRUDA growth, lower adult vaccination utilization, modestly lower gross margin, higher operating expenses, the QLEX European injunctions, and withdrawal of the ifinatamab deruxtecan application. Highlights significantly outweighed the lowlights.View all IT:1MRKX earnings summaries1MRKX Sales Breakdown
89.43% Pharmaceutical
9.77% Animal Health
0.79% Other
1MRKX Stock 12 Month Forecast
Average Price Target
€144.34
▲(12.16% Upside)